In one of his first experiences with death, Joshua Rarick, MD, now a fourth-year general surgery resident at Covenant ...

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a ...

Valley Fever cases are increasing in California. Over 3,100 cases are confirmed in early 2025. This is more than last year.

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. My name is Rochelle, and I will be your ...

At this time, I would like to welcome everyone to the MiNK Therapeutics first quarter 2025 financial results. After the speaker remarks, there will be a question-and-answer session. If you would like ...

Nipah’s deadly shadow returns to Malappuram, sparking a frantic race against time to contain the virus. Abdul Latheef Naha ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed ...

MediciNova, Inc.’s MNOV share price has dipped by 6.16%, which has investors questioning if this is right time to buy.

In the worst cases, it is possible to develop more serious complications like acute respiratory distress syndrome and ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

Higher initial doses of surfactant for the prevention or treatment of respiratory distress syndrome in preterm infants (Protocol). Cochrane Database of Systematic Reviews 2025, Issue 4. Art. No.: ...

Background: Acute respiratory infections (ARIs) are a leading cause of morbidity in children. Understanding the distribution of respiratory pathogens is crucial for effective prevention and treatment.